Literature DB >> 16914273

Encapsulation of antigenic extracts of Salmonella enterica serovar. Abortusovis into polymeric systems and efficacy as vaccines in mice.

Maite Estevan1, Juan M Irache, María Jesús Grilló, Jose M Blasco, Carlos Gamazo.   

Abstract

The properties of drug-vaccine delivery systems based on the use of biodegradable polymers, and its application in the control of experimental infection by Salmonella enterica serovar. Abortusovis (SAO), are described in this manuscript. Micelles of major membrane antigens from SAO (HSao extract) can be encapsulated in microparticles of poly(epsilon-caprolactone) or in nanoparticles of Gantrez polymer. The encapsulation process was optimized by the combined use of cyclodextrins. The resulting particles contained unaltered significant amounts of the antigenic complex. To establish the protective value of these subunit vaccines, particles were injected in one single dose (20 microg of HSao) subcutaneously in BALB/c mice in order to observe the protection conferred against experimental infection with the virulent strains S. Abortusovis 15/5. Control non-immunized animals resulted infected, as well as the group that received unloaded or HSao loaded into microparticles. In contrast, nanoparticles conferred a significant protection when compared to unvaccinated controls, similar to that induced by the attenuated commercial vaccine Rv6. In conclusion, protection against experimental infection in mice after one single shoot, and its potential for mucosal vaccination suggest that HSao-nanoparticles may represent a serious alternative to the conventional attenuated vaccines against S. Abortusovis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914273     DOI: 10.1016/j.vetmic.2006.07.004

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  8 in total

1.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

2.  Novel antigen delivery technologies: a review.

Authors:  Deepika Jain; Vikas Jain; Ranjit Singh
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

3.  The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle.

Authors:  A M Arenas-Gamboa; T A Ficht; M M Kahl-McDonagh; G Gomez; A C Rice-Ficht
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

Review 4.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

5.  Virulence of 32 Salmonella strains in mice.

Authors:  Matthew C Swearingen; Steffen Porwollik; Prerak T Desai; Michael McClelland; Brian M M Ahmer
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

6.  The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice.

Authors:  Beatriz San Román; Victoria Garrido; Pilar-María Muñoz; Laura Arribillaga; Begoña García; Ximena De Andrés; Virginia Zabaleta; Cristina Mansilla; Inmaculada Farrán; Iñigo Lasa; Damián De Andrés; Beatriz Amorena; Juan-José Lasarte; María-Jesús Grilló
Journal:  Vet Res       Date:  2012-04-19       Impact factor: 3.683

7.  Protection Conferred by Drinking Water Administration of a Nanoparticle-Based Vaccine against Salmonella Enteritidis in Hens.

Authors:  Javier Ochoa-Repáraz; Eduard Sebastià; Marta Sitjà; Ibai Tamayo; Juan Manuel Irache; Carlos Gamazo
Journal:  Vaccines (Basel)       Date:  2021-03-03

Review 8.  Cyclodextrins in the antiviral therapy.

Authors:  László Jicsinszky; Katia Martina; Giancarlo Cravotto
Journal:  J Drug Deliv Sci Technol       Date:  2021-05-20       Impact factor: 3.981

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.